HIV / AIDS in the News

Flu Drugs Show Promise Against Cognitive Decline, Aging-Related Diseases - poz.com

 

As HIV cases rise among young men in Karnataka, dating apps complicate contact tracing - The South First

 

Plunging HIV Budgets Cast Dark Shadow Over UN High-Level Meeting - Health Policy Watch

 

The American Academy of HIV Medicine et al. v. U.S. Department of Health and Human Services et al. - Lambda Legal

 

Health Equity in HIV - Centers for Disease Control and Prevention | CDC (.gov)

 

Phase 3 Trials Support Oral, Once-Weekly Islatravir/Lenacapavir for HIV - Infectious Disease Advisor

 

Pitavastatin Reduces Incident Hypertension Risk in Individuals With HIV - Infectious Disease Advisor

 

South Africa Could Begin Local Manufacturing Of HIV Drug Lenacapavir Generic - Eurasia Review

 

Mehdi Benlarbi awarded the Uta von Schwedler Prize - Université de Montréal

 

Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study - Yahoo Finance

 

GILD: Strong pipeline, strategic acquisitions, and long-acting HIV therapies drive long-term growth - TradingView

 

Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study - Zacks Investment Research

 

Once Weekly Oral HIV Regimen Maintains Viral Suppression - Drug Topics

 

Gilead Balances Trodelvy Setback With Once Weekly HIV Progress - simplywall.st

 

Semaglutide Tied to Aging Clocks in HIV - Conexiant

 

Gilead’s Mixed Trial News Puts HIV Progress And Oncology Risks In Focus - Yahoo Finance

 

Merck, Gilead report mixed outcomes in key lung cancer, HIV studies - BioPharma Dive

 

HIV-Related Stigma and Its Impact Across the HIV Care Continuum: Implications for Testing, Treatment, and Long-Term Retention - Cureus

 

HIV-Related Stigma and Its Impact Across the HIV Care Continuum: Implications for Testing, Treatment, and Long-Term Retention - Cureus

 

Semaglutide and aging: New study finds benefits beyond weight loss - Medical News Today

 

Merck, Gilead score in effort to develop the first weekly HIV pill - Fierce Pharma

 

Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden - Medical Xpress

 

Trodelvy misses again in lung cancer, but Gilead and Merck have an HIV success to soften the blow - Endpoints News

 

Gilead and MSD’s once-weekly HIV pill meets primary endpoints in Phase III trials - Clinical Trials Arena

 

Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden - Toronto Star

 

Revealing the assembly of HIV's integration complex - Drug Discovery News

 

Sustaining HIV Impact in MENA: Community Coalitions and Regional Coordination and Leadership - Policy Brief - ReliefWeb

 

Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble - BioSpace

 

Staggering Results Show HIV-Transmission Reduced 100% with Twice-Yearly Lenacapavir Injection - Good News Network

 

South Africa launches HIV prevention drug lenacapavir in the country - swiowanewssource.com